A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Clinical trial NCT05323656 · COMPLETED
Trial details
- NCT number
- NCT05323656
- Sponsor
- Calliditas Therapeutics Suisse SA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-06
- Primary completion
- 2024-02-18
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.